Monopar Therapeutics has disclosed recent stock transactions by its director, Christopher M. Starr, in a filing with the SEC. This update is significant as it illustrates active management of shares by company insiders, which can influence investor perceptions and market dynamics.
Background
Monopar Therapeutics, identified by the SIC code 2834, specializes in pharmaceutical preparations. The company trades under the ticker MNPR on the Nasdaq exchange. As a smaller reporting company, Monopar is subject to specific regulatory requirements and has been active in filing various forms with the SEC.
What the Filing Says
According to the filing dated October 5, 2026, Starr reported multiple transactions involving Monopar's common stock. Notably, he acquired 8,400 shares at a price of $0.005 per share and disposed of shares in several transactions at prices ranging from $77.50 to $80.01. The filing states, "This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026." Following these transactions, Starr holds 13,573 shares directly and additional shares held in a trust.
Impact
These transactions may affect investor sentiment towards Monopar Therapeutics, particularly as they indicate insider confidence in the company's future. The pharmaceutical preparations industry is known for its volatility, and such insider activities can serve as indicators of management's outlook.
What's Next
The filing does not say what happens next.